Medtronic hires Yale to review InFuse following safety questions

Medtronic Inc. (NYSE:MDT) commissioned Yale University to review the safety and efficacy of Medtronic's bone repair product InFuse Bone Graft. The move follows reports published in the Spine Journal in June alleging that the company failed to disclose financial ties to medical researchers involved in InFuse trials. The reports also claimed those same researchers failed to report the risk of complications associated with InFuse. Separately, the U.S. Senate Finance Committee is investigating Medtronic over the concerns. ...